GlassScriptPhysician profile
Michael L Larson
NPI 1710905195
$3,008.48
in general payments reported to CMS, 2019-2025
29 companies · $546 in 2025
The $546 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $725 · 2022: $542 · 2023: $764 · 2024: $432 · 2025: $546.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,741.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,741.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $639.15 | 2021-2024 | Xarelto |
| Lilly USA, LLC | $273.14 | 2021-2025 | Mounjaro, Jardiance, Emgality |
| Amgen INC. | $265.30 | 2023-2025 | Repatha, Otezla, Otezla |
| Novo Nordisk INC | $242.06 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $183.87 | 2021-2025 | Farxiga, Airsupra |
| Daiichi Sankyo INC. | $170.17 | 2021-2022 | |
| Abbott Laboratories | $169.30 | 2021-2025 | Freestyle Libre 3, Octrode |
| Boehringer Ingelheim Pharmaceuticals, INC. | $134.07 | 2022-2025 | Jardiance, Tradjenta |
| Bayer Healthcare Pharmaceuticals INC. | $122.13 | 2021-2025 | |
| Optinose US, INC. | $114.65 | 2023 | |
| Glaxosmithkline, LLC. | $87.84 | 2021-2024 | Arexvy, Shingrix, Trelegy Ellipta |
| Pfizer INC. | $75.51 | 2021-2025 | |
| Inspire Medical Systems, INC. | $73.34 | 2023-2024 | Inspire |
| Abbvie INC. | $68.97 | 2021-2023 | |
| Almatica Pharma LLC | $55.06 | 2022-2025 | Loreev Xr |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $42.78 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $42.13 | 2025 | Xifaxan |
| Amarin Pharma, INC. | $40.12 | 2021 | |
| Exact Sciences Corporation | $39.38 | 2023-2025 | Cologuard Collection Kit |
| Antares Pharma, INC. | $20.03 | 2022 | |
| Medtronic, INC. | $19.60 | 2025 | Inceptiv |
| Hologic Sales and Service, LLC | $18.92 | 2024 | Thinprep 2000 Processor |
| Idorsia Pharmaceuticals US INC | $18.50 | 2023 | Quviviq |
| Otsuka America Pharmaceutical, INC. | $18.37 | 2025 | Rexulti |
| Sumitomo Pharma America, INC. | $16.85 | 2025 | Gemtesa |
| Hikma Pharmaceuticals USA | $14.99 | 2021 | |
| Eyevance Pharmaceuticals LLC | $14.99 | 2021 | |
| Esperion Therapeutics, INC. | $14.42 | 2021 | |
| Dexcom, INC. | $12.84 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Larson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.